IDEAS home Printed from https://ideas.repec.org/a/wly/mgtdec/v45y2024i4p2196-2209.html
   My bibliography  Save this article

To merge or not to merge? The impact of mergers and acquisitions on corporate success in the pharmaceutical industry

Author

Listed:
  • Melanie Büssgen
  • Tom Stargardt

Abstract

Two of the chief goals of most companies are to secure their own existence and generate above‐average returns for their owners. One of the main ways that companies attempt to achieve these goals is to grow, and pharmaceutical companies are no exception in this regard. However, whereas internal growth tends to be organic and slow, external growth can usually be achieved more quickly, for example, through mergers, acquisitions or other external transactions. The aim of this study is to evaluate the impact of merger and acquisition (M&A) activities on pharmaceutical company success, measured in terms of financial and other performance indicators. We identified the top 30 pharmaceutical companies worldwide by revenue in 2020 and gathered data on M&A activities and a broad range of financial and other performance indicators from 2000 to 2020. We then used a generalised difference‐in‐difference design to evaluate the extent to which a company's success was affected by substantial M&A activities versus organic growth. To do so, we defined a premerger period of 2 years and a postmerger period of 3 years. We classified M&A activities as substantial when transaction costs were greater than 20% of a company's annual revenue. Our results indicate that there is a clear trend for M&As to have a positive impact on corporate success compared with organic growth. For example, after an M&A, a company's annual revenue increased on average by 3.50 billion United States dollars (USD) (p = 0.000) in the first year and by 4.52 billion USD (p = 0.000) in the second year. For employee growth, we found significant increases across all time periods (p = 0.000). Postmerger increases were also seen in gross profit in the first (+1.65 billion USD, p = 0.053) and second (+2.61 billion USD, p = 0.005) years, as well as in net profit (+6.82 billion USD, p = 0.014) and return on assets in the first year (+12.04 percentage points, p = 0.016). However, indicators of innovation (e.g. research and development [R&D] spending) and of stakeholder value (e.g. market capitalisation) did not show a significant increase. Compared with the impact of organic growth alone, M&A activities in the pharmaceutical industry led to significantly higher market dominance, size and profits but did not have a significant impact on innovation or shareholder value over the short time.

Suggested Citation

  • Melanie Büssgen & Tom Stargardt, 2024. "To merge or not to merge? The impact of mergers and acquisitions on corporate success in the pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 45(4), pages 2196-2209, June.
  • Handle: RePEc:wly:mgtdec:v:45:y:2024:i:4:p:2196-2209
    DOI: 10.1002/mde.4129
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/mde.4129
    Download Restriction: no

    File URL: https://libkey.io/10.1002/mde.4129?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Comanor, William S. & Scherer, F.M., 2013. "Mergers and innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 32(1), pages 106-113.
    2. Renneboog, Luc & Vansteenkiste, Cara, 2019. "Failure and success in mergers and acquisitions," Journal of Corporate Finance, Elsevier, vol. 58(C), pages 650-699.
    3. Wilfred Dolfsma & Gerben Velde, 2014. "Industry innovativeness, firm size, and entrepreneurship: Schumpeter Mark III?," Journal of Evolutionary Economics, Springer, vol. 24(4), pages 713-736, September.
    4. Patricia M. Danzon & Andrew Epstein & Sean Nicholson, 2007. "Mergers and acquisitions in the pharmaceutical and biotech industries," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 307-328.
    5. Zoltan J. Acs & David B. Audretsch, 2008. "Innovation, Market Structure, and Firm Size," Chapters, in: Entrepreneurship, Growth and Public Policy, chapter 2, pages 16-23, Edward Elgar Publishing.
    6. Renneboog, Luc & Vansteenkiste, Cara, 2019. "Failure and success in mergers and acquisitions," Journal of Corporate Finance, Elsevier, vol. 58(C), pages 650-699.
    7. K D S Fernald & H P G Pennings & J F van den Bosch & H R Commandeur & E Claassen, 2017. "The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-22, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Wang, Shuxun & Wu, Kai & Lai, Seiwai, 2022. "Acquisition for innovations? M&A intensity and intra-firm innovation reallocations," Research in International Business and Finance, Elsevier, vol. 62(C).
    2. Birhanu, Addis & Geiler, Philipp & Renneboog, Luc & Zhao, Yang, 2021. "Acquisition experience and director remuneration," Other publications TiSEM 6c1d41ae-5e2a-4868-b1af-1, Tilburg University, School of Economics and Management.
    3. Chan, K. Hung & He, Miao & Mo, Phyllis Lai Lan & Zhang, Weiyin, 2024. "Long-term tax strategy and corporate acquisition payment structure: An analysis based on the book-tax tradeoff theory," Journal of Contemporary Accounting and Economics, Elsevier, vol. 20(3).
    4. Pombo, Carlos & Pinto-Gutierrez, Cristian & Jara-Bertín, Mauricio, 2024. "Blockholder voting power and investment decisions: Evidence from cross-border deals in Latin America," Journal of Economics and Business, Elsevier, vol. 131(C).
    5. Zhu, Bing & Xia, Xiaoxue & Zheng, Xiaojia, 2021. "One way out of the share pledging quagmire: Evidence from mergers and acquisitions," Journal of Corporate Finance, Elsevier, vol. 71(C).
    6. repec:hal:journl:hal-03265164 is not listed on IDEAS
    7. repec:diw:diwwpp:dp2073 is not listed on IDEAS
    8. Quyen Van & Vy Tran, 2023. "Control of Emerging-Market Target, Abnormal Stock Return: Evidence in Vietnam," Papers 2302.07117, arXiv.org, revised Mar 2023.
    9. Zhou, Chensong & Zhang, Xiangzhi & Xiong, Lingyun & Chen, Chuanyong, 2023. "Merger and acquisition performance commitments and shareholding reductions," Finance Research Letters, Elsevier, vol. 57(C).
    10. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    11. Tannista Banerjee & Arnab Nayak, 2015. "Comparing Domestic and Cross-Border Mergers and Acquisitions in the Pharmaceutical Industry," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 43(4), pages 489-499, December.
    12. Li, Hui & Wu, Dongdong, 2024. "Online investor attention and firm restructuring performance: Insights from an event-based DEA-Tobit model," Omega, Elsevier, vol. 122(C).
    13. Carlos Pombo & Cristian Pinto-Gutierrez & Mauricio Jara-Betín, 2022. "Multiple large shareholder coalitions, institutional ownership and investment decisions: Evidence from cross-border deals in Latin America," Documentos CEDE 20333, Universidad de los Andes, Facultad de Economía, CEDE.
    14. Birhanu, Addis Gedefaw & Geiler, Philipp & Renneboog, Luc & Zhao, Yang, 2021. "Acquisition experience and director remuneration," Journal of International Financial Markets, Institutions and Money, Elsevier, vol. 75(C).
    15. Anton George & Cheptiş Alexandra & Vasilca Miruna-Mihaela & Vid Alin-Ioan, 2022. "Estimating the value creation probability of mergers and acquisitions events using option pricing models Evidence from Europe and USA," Proceedings of the International Conference on Business Excellence, Sciendo, vol. 16(1), pages 203-216, August.
    16. Cœuré, Benoît & König, Elke & Krahnen, Jan Pieter & Huizinga, Harry & Schlegel, Jonas, 2024. "Winners and losers in bank resolution: Recent examples and a modest reform proposal," SAFE White Paper Series 106, Leibniz Institute for Financial Research SAFE.
    17. Haucap, Justus & Rasch, Alexander & Stiebale, Joel, 2019. "How mergers affect innovation: Theory and evidence," International Journal of Industrial Organization, Elsevier, vol. 63(C), pages 283-325.
    18. Yiannis Anagnostopoulos & George Alexandrou & Hardy M. Thomas, 2024. "European banking M&As: The role of financial advisors," Review of Quantitative Finance and Accounting, Springer, vol. 63(4), pages 1193-1231, November.
    19. Tunyi, Abongeh A. & Machokoto, Michael, 2021. "The impact of weather-induced moods on M&A performance," Economics Letters, Elsevier, vol. 207(C).
    20. Hussain, Tanveer & Loureiro, Gilberto, 2022. "Portability of firm corporate governance in mergers and acquisitions," Research in International Business and Finance, Elsevier, vol. 63(C).
    21. Bao, Yangming & Li, Jie, 2024. "Cross-border M&A, gender-equal culture, and board gender diversity," Journal of Corporate Finance, Elsevier, vol. 84(C).
    22. Hussain, Tanveer & Loureiro, Gilberto, 2023. "Target industry takeover competition and the wealth effects of mergers and acquisitions: International evidence," Journal of International Financial Markets, Institutions and Money, Elsevier, vol. 89(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:mgtdec:v:45:y:2024:i:4:p:2196-2209. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/7976 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.